Literature DB >> 3358396

Infection rates of Broviac-Hickman catheters and implantable venous devices.

C L Wurzel1, K Halom, J G Feldman, L G Rubin.   

Abstract

We retrospectively identified and prospectively followed up 62 patients with 78 venous-access catheters over a 30-month period (15773 catheter-days) to compare infectious complications of Broviac-Hickman catheters (n = 33) and totally implantable. venous devices (n = 45) in pediatric oncology patients. Demographic data and characteristics of catheter use were comparable for both groups. Significantly associated with the risk of a catheter-associated infection were (1) the percentage of time the patient was neutropenic and (2) a patient age of younger than 2 years. In the Broviac-Hickman catheter group, 14 catheter-associated infections occurred in 27% of patients using catheters for an infection rate of 0.21/100 catheter-days. In the implantable venous device group, 13 infections occurred in 24% of patients using catheters for an infection rate of 0.14/100 catheter-days. The relative risk of infection from Broviac-Hickman catheters compared with implantable venous devices was 1.5, which was not significant (95% confidence interval, 0.7 to 3.2). Thus, the incidence of infectious complications was comparable for both catheter types.

Entities:  

Mesh:

Year:  1988        PMID: 3358396     DOI: 10.1001/archpedi.1988.02150050074036

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  16 in total

Review 1.  Complications of long-term home total parenteral nutrition: their identification, prevention and treatment.

Authors:  A L Buchman
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

2.  Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports).

Authors:  T U Anthony; L G Rubin
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Catheter-related infections in pediatric patients with cancer.

Authors:  V Cecinati; L Brescia; L Tagliaferri; P Giordano; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-03       Impact factor: 3.267

4.  epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox
Journal:  J Hosp Infect       Date:  2014-01       Impact factor: 3.926

5.  Single-incision technique for placement of tunneled internal jugular vein vascular access in children.

Authors:  Marian Gaballah; Ganesh Krishnamurthy; Marc S Keller; Adeka McIntosh; Anne Marie Cahill
Journal:  Pediatr Radiol       Date:  2014-03-11

6.  Central venous catheter tip position and malfunction in a paediatric oncology unit.

Authors:  H Lucas; S P Attard-Montalto; V Saha; A Bristow; J E Kingston; O B Eden
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

7.  Retention of drugs in venous access port chamber: a note of caution.

Authors:  M Ben-Arush; M Berant
Journal:  BMJ       Date:  1996-02-24

8.  Catheter-Related Complications in Children With Cancer Receiving Parenteral Nutrition: Change in Risk Is Moderated by Catheter Type.

Authors:  Melissa A Shenep; Mary R Tanner; Yilun Sun; Tina Culley; Randall T Hayden; Patricia M Flynn; Li Tang; Joshua Wolf
Journal:  JPEN J Parenter Enteral Nutr       Date:  2016-01-07       Impact factor: 4.016

9.  The use of an implantable central venous (Hickman) catheter for long-term venous access in dogs undergoing bone marrow transplantation.

Authors:  A C Abrams-Ogg; S A Kruth; R F Carter; V E Valli; S Kamel-Reid; I D Dubé
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

10.  A prospective, randomized evaluation of the effect of silver impregnated subcutaneous cuffs for preventing tunneled chronic venous access catheter infections in cancer patients.

Authors:  J S Groeger; A B Lucas; D Coit; M LaQuaglia; A E Brown; A Turnbull; P Exelby
Journal:  Ann Surg       Date:  1993-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.